DK0706563T3 - Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetet - Google Patents
Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetetInfo
- Publication number
- DK0706563T3 DK0706563T3 DK94916597T DK94916597T DK0706563T3 DK 0706563 T3 DK0706563 T3 DK 0706563T3 DK 94916597 T DK94916597 T DK 94916597T DK 94916597 T DK94916597 T DK 94916597T DK 0706563 T3 DK0706563 T3 DK 0706563T3
- Authority
- DK
- Denmark
- Prior art keywords
- kgf
- keratonocyte
- decreased
- growth factor
- biological activity
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000057239 human FGF7 Human genes 0.000 abstract 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8642793A | 1993-06-29 | 1993-06-29 | |
| PCT/US1994/004694 WO1995001434A1 (en) | 1993-06-29 | 1994-04-28 | A truncated keratinocyte growth factor (kgf) having increased biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0706563T3 true DK0706563T3 (da) | 2005-01-31 |
Family
ID=22198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94916597T DK0706563T3 (da) | 1993-06-29 | 1994-04-28 | Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetet |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US5677278A (enExample) |
| EP (2) | EP0706563B1 (enExample) |
| JP (4) | JP3570516B2 (enExample) |
| KR (1) | KR960703433A (enExample) |
| CN (1) | CN1129955A (enExample) |
| AT (1) | ATE278777T1 (enExample) |
| AU (1) | AU681405B2 (enExample) |
| BG (1) | BG100236A (enExample) |
| BR (1) | BR9407035A (enExample) |
| CA (1) | CA2166278A1 (enExample) |
| CZ (1) | CZ343795A3 (enExample) |
| DE (2) | DE69434053T2 (enExample) |
| DK (1) | DK0706563T3 (enExample) |
| ES (1) | ES2227527T3 (enExample) |
| FI (1) | FI956203A7 (enExample) |
| FR (1) | FR06C0004I2 (enExample) |
| HU (1) | HUT73453A (enExample) |
| LU (1) | LU91215I2 (enExample) |
| NL (1) | NL300217I2 (enExample) |
| NO (1) | NO955189D0 (enExample) |
| NZ (1) | NZ266622A (enExample) |
| PL (1) | PL312257A1 (enExample) |
| PT (1) | PT706563E (enExample) |
| SK (1) | SK153295A3 (enExample) |
| WO (1) | WO1995001434A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026291B1 (en) | 1989-01-31 | 2006-04-11 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
| GEP20022681B (en) | 1989-01-31 | 2002-04-25 | Aaronson Us Stuart A | Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth |
| US5814605A (en) * | 1993-03-26 | 1998-09-29 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| US7084119B2 (en) * | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| BR9407035A (pt) * | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
| SI0785949T1 (en) * | 1994-10-13 | 2003-08-31 | Amgen Inc. | Method for purifying keratinocyte growth factors |
| US6008328A (en) * | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
| AU745815B2 (en) * | 1994-10-13 | 2002-04-11 | Biovitrum Ab (Publ) | Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using |
| CN1168678A (zh) * | 1994-10-13 | 1997-12-24 | 安姆根有限公司 | 用kgf治疗糖尿病的方法 |
| US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
| ES2293137T3 (es) * | 1995-10-11 | 2008-03-16 | Novartis Vaccines And Diagnostics, Inc. | Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas. |
| US6692961B1 (en) | 1996-10-11 | 2004-02-17 | Invitrogen Corporation | Defined systems for epithelial cell culture and use thereof |
| DK0935652T3 (da) * | 1996-10-15 | 2004-07-26 | Amgen Inc | Keratinocyt vækstfaktor-2 produkter |
| US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
| US20030144202A1 (en) * | 1996-10-15 | 2003-07-31 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
| EP1473366A1 (en) * | 1996-10-15 | 2004-11-03 | Amgen Inc. | Keratinocyte growth factor-2 products |
| JP2002513294A (ja) * | 1997-06-19 | 2002-05-08 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
| US20080233086A1 (en) * | 1997-09-05 | 2008-09-25 | Canbiocin Inc. | Expression Vectors for Treating Bacterial Infections |
| US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| KR20010033484A (ko) | 1997-12-22 | 2001-04-25 | 휴먼 게놈 사이언시즈, 인크. | 각질세포 성장 인자-2 제제 |
| US6599879B1 (en) * | 1998-02-13 | 2003-07-29 | Human Genome Sciences, Inc. | Therapeutic uses of keratinocyte growth factor-2 |
| DE19934510B4 (de) * | 1999-07-22 | 2009-04-16 | Vermicon Ag | Verfahren zum Nachweis von Mikroorganismen |
| WO2001027301A2 (en) | 1999-10-15 | 2001-04-19 | The Rockefeller University | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
| DE10024334B4 (de) * | 2000-05-17 | 2006-06-01 | Medigene Ag | Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat |
| AU2002236477A1 (en) | 2000-11-21 | 2002-06-03 | The Texas A & M University System | Fgf-affinity chromatography |
| EP1357931A2 (en) * | 2001-01-08 | 2003-11-05 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| AU2002256624B2 (en) | 2001-02-19 | 2007-12-06 | Merck Patent Gmbh | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
| JP2005500390A (ja) * | 2001-08-21 | 2005-01-06 | カイロン コーポレイション | Ｋｇｆポリペプチド組成物 |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| CA2589889C (en) * | 2004-12-15 | 2013-07-30 | Amgen Inc. | Therapeutic formulations of keratinocyte growth factor |
| US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
| AU2006335256B2 (en) * | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| WO2008005533A2 (en) * | 2006-07-06 | 2008-01-10 | Aaron Thomas Tabor | Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
| KR101021197B1 (ko) * | 2008-04-11 | 2011-03-11 | (주)케어젠 | 성장인자―미미킹 펩타이드 및 그의 용도 |
| US9132202B2 (en) | 2009-07-17 | 2015-09-15 | Aaron T. Tabor | Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
| MX2016005614A (es) | 2013-11-01 | 2016-12-09 | Spherium Biomed S L | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. |
| JP2024532086A (ja) | 2021-08-30 | 2024-09-05 | ユニケム ラボラトリーズ リミテッド | 炎症性疾患の処置のためのタンパク質組成物 |
| KR102691028B1 (ko) * | 2021-11-15 | 2024-08-05 | (주)피앤피바이오팜 | 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20022681B (en) * | 1989-01-31 | 2002-04-25 | Aaronson Us Stuart A | Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5814605A (en) | 1993-03-26 | 1998-09-29 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| BR9407035A (pt) | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
| MX9702665A (es) | 1994-10-13 | 1997-07-31 | Amgen Inc | Analogos del factor de crecimiento de queratinocitos. |
| CN1168678A (zh) | 1994-10-13 | 1997-12-24 | 安姆根有限公司 | 用kgf治疗糖尿病的方法 |
-
1994
- 1994-04-28 BR BR9407035A patent/BR9407035A/pt not_active Application Discontinuation
- 1994-04-28 PL PL94312257A patent/PL312257A1/xx unknown
- 1994-04-28 EP EP94916597A patent/EP0706563B1/en not_active Expired - Lifetime
- 1994-04-28 NZ NZ266622A patent/NZ266622A/en unknown
- 1994-04-28 EP EP04023638A patent/EP1493812A3/en not_active Ceased
- 1994-04-28 CA CA002166278A patent/CA2166278A1/en not_active Abandoned
- 1994-04-28 JP JP50346495A patent/JP3570516B2/ja not_active Expired - Fee Related
- 1994-04-28 CZ CZ953437A patent/CZ343795A3/cs unknown
- 1994-04-28 WO PCT/US1994/004694 patent/WO1995001434A1/en not_active Ceased
- 1994-04-28 DK DK94916597T patent/DK0706563T3/da active
- 1994-04-28 AU AU68208/94A patent/AU681405B2/en not_active Ceased
- 1994-04-28 HU HU9503857A patent/HUT73453A/hu unknown
- 1994-04-28 DE DE69434053T patent/DE69434053T2/de not_active Expired - Lifetime
- 1994-04-28 ES ES94916597T patent/ES2227527T3/es not_active Expired - Lifetime
- 1994-04-28 PT PT94916597T patent/PT706563E/pt unknown
- 1994-04-28 KR KR1019950705997A patent/KR960703433A/ko not_active Ceased
- 1994-04-28 AT AT94916597T patent/ATE278777T1/de active
- 1994-04-28 CN CN94193193A patent/CN1129955A/zh active Pending
- 1994-04-28 DE DE1994634053 patent/DE122006000005I2/de active Active
- 1994-04-28 SK SK1532-95A patent/SK153295A3/sk unknown
-
1995
- 1995-03-27 US US08/410,941 patent/US5677278A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,937 patent/US5863767A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,546 patent/US5773586A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,547 patent/US5843883A/en not_active Expired - Lifetime
- 1995-12-20 BG BG100236A patent/BG100236A/xx unknown
- 1995-12-20 NO NO955189A patent/NO955189D0/no unknown
- 1995-12-22 FI FI956203A patent/FI956203A7/fi unknown
-
1998
- 1998-05-08 US US09/074,950 patent/US6074848A/en not_active Expired - Lifetime
-
2000
- 2000-05-16 US US09/573,068 patent/US6677301B1/en not_active Expired - Fee Related
-
2004
- 2004-02-10 JP JP2004034289A patent/JP2004166709A/ja not_active Withdrawn
-
2005
- 2005-11-17 JP JP2005333438A patent/JP2006075173A/ja not_active Withdrawn
-
2006
- 2006-01-26 NL NL300217C patent/NL300217I2/nl unknown
- 2006-01-27 LU LU91215C patent/LU91215I2/en unknown
- 2006-01-31 FR FR06C0004C patent/FR06C0004I2/fr active Active
-
2007
- 2007-06-11 US US11/811,560 patent/US20090093400A1/en not_active Abandoned
-
2008
- 2008-11-26 JP JP2008301630A patent/JP4662569B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434053D1 (de) | Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität | |
| ATE295414T1 (de) | Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen | |
| DE69024862D1 (de) | Modifiziertes, biologisch aktives Protein | |
| DE3751842D1 (de) | Modifizierter, menschlicher Gewebeplasminogenaktivator und seine Herstellung | |
| DE69024104D1 (de) | Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase | |
| DE69126049D1 (de) | Vektoren und Zusammensetzungen zur Expression von Glykosilationsmutanten des menschlichen Proteins-C | |
| ES2061823T3 (es) | Nueva proteina h que es capaz de fijarse a igg, gen que codifica dicha proteina h, y un procedimiento para producir dicha proteina h. | |
| DE69225597D1 (de) | Peptide mit einer lanthionin-brücke | |
| FI945626A0 (fi) | Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi | |
| BR9002253A (pt) | Valvula reguladora com compensacao de queda | |
| AU3095892A (en) | Human type antibody reactive with GPIIb/IIIa | |
| ATE209252T1 (de) | Rekombinante d-hydantoinase, verfahren zur herstellung und verwendung | |
| ATE145939T1 (de) | Mitogen für die glatte muskulatur und dessen kodierende dns | |
| IT1231764B (it) | Composizione poliuretanica con capacita' di assorbire umidita', particolarmente adatta per la fabbricazione di cuoio sintetico e simili, e procedimento per la sua produzione. | |
| EP0254272A3 (en) | The use of probucol for preventing and treating heart diseases | |
| EP0206329A3 (en) | Sprung floor | |
| EP0749981A4 (en) | MONOCLONAL ANTIBODY | |
| IT219518Z2 (it) | Leva di comando particolarmente per l'azionamento di gruppi valvolari | |
| DK349787D0 (da) | 1,2,3-thiadiazol-4-thiolater samt n3-thioacylsemicarbazider |